가와사끼병의 급성기 치료에서 고용량 아스피린과 고용량 이부프로펜 사용 효과 비교 분석 = Comparison and analysis of the effectiveness to high dose of aspirin and ibuprofen in acute phase of Kawasaki disease

다국어 초록 (Multilingual Abstract)

Purpose : We evaluated the effectiveness of treatment and cardiac complications of replacing a high dose of aspirin with a high dose of ibuprofen for children in acute phase of Kawasaki disease. We also analyzed the possibility of replacing a high dose of aspirin with a high dose of ibuprofen to prevent complications such as Reye’s syndrome caused by aspirin.
Methods : One hundred eight children with Kawasaki disease were admitted in the pediatrics department from January 1, 2004 to December 31, 2008. Echocardiography and laboratory tests were performed during diagnosis, and the children were followed-up at 6-8 weeks after the diagnosis. We retrospectively analyzed their characteristics and clinical results.
Results : The children were assigned to receive either a high dose of aspirin with intravenous immunoglobulin (IVIG) (aspirin group) or a high dose of ibuprofen with IVIG (ibuprofen group). A total of 55 and 53 children were included in the aspirin and ibuprofen groups, respectively. The mean defervescence period was 6.5±2.1 days in the aspirin group, and 6.9±1.9 days in the ibuprofen group (P=0.309). The number of failed treatments, during and after treatment, was 8 in the aspirin group and 10 in the ibuprofen group (P=0.547). There were 11 initial cardiac complications in the aspirin group, and 14 in the ibuprofen group, but children who showed improvement at follow-up was 7 and 13 in the aspirin and ibuprofen groups, respectively (P= 0.133). Laboratory findings were also improved in both groups.
Conclusion : We can be considered whether we will replace high dose of aspirin by high dose of ibuprofen in acute phase of Kawasaki disease. Therefore, we can prevent the severe complications of aspirin use, such as Reye’s syndrome.

국문 초록 (Abstract)

목 적 : 합병증으로 관상동맥 질환을 일으킬 수 있는 가와사끼병의 급성기 치료에 있어 정맥용 면역 글로불린과 함께 투여하는 고용량 아스피린을 고용량 이부프로펜으로 대체하여 투약시 효과와 가와사끼병의 합병증 발생 빈도를 비교 및 분석함으로서 Reye 증후군과 같은 합병증을 유발할 수 있는 아스피린을 이보다 부작용이 적은 이부프로펜과 같은 다른 비스테로이드 항염제로의 대체 가능성을 분석하였다.
방 법 : 2004년 1월 1일부터 2008년 12월 31일까지 익산 원광대학병원 소아과에 108명의 소아가 가와사끼병으로 진단받았다. 심장 초음파 검사와 혈액 검사를 진단 시점과 진단 약 6-8주 후 시행하여 비교하였다. 본 저자들은 대상 환아들의 특성과 검사소견을 기초로 후향적으로 비교분석하였다.
결 과 : 총 108명의 환아들을 정맥용 면역글로불린 투여 및 고용량 아스피린을 사용했던 군(아스피린 군)과 정맥용 면역글로불린 투여 및 고용량 이부프로펜을 사용했던 군(이부프로펜 군)으로 분류하였다. 아스피린 군은 55명이었고 이부프로펜 군은 53명이었다. 평균 해열 기간은 발열 후 아스피린 군 6.5±2.1일, 이부프로펜 군 6.9±1.9일이었다(P=0.309). 치료 중이나 후 치료실패 환아는 아스피린 군 8명, 이부프로펜 군 10명이었다(P=0.547). 재발한 환아는 아스피린 군 2명, 이부프로펜 군 1명이었다(P= 0.580). 혈액 검사에서도 두 군에서 호전된 소견을 보였다.
결 론 : 본 저자들은 가와사끼병 급성기에 있어 정맥용 면역 글로불린과 더불어 사용하고 있는 고용량 아스피린 투약에 있어 이부프로펜과 같은 비스테로이드 항염제를 대체하여 투약할 수 있을 것으로 생각되며 이에 Reye 증후군과 같은 아스피린의 치명적인 합병증을 예방할 수 있을 것이다.

참고문헌 (Reference)

1 Hsieh KS, "Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited" 114 : e689-e693, 2004

2 Newburger JW, "The treatment of Kawasaki syndrome with intravenous gamma globulin" 315 : 341-347, 1986

3 Yasukawa K, "Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease" 105 : 766-769, 2002

4 Baumer JH, "Salicylate for the treatment of Kawasaki disease in children" 18 : CD004175-, 2006

5 Research Committee on Kawasaki disease, "Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease" Japenase Ministry of Health and Welfare 1984

6 Leung DY, "Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease" 140 : 742-746, 2002

7 Terai M, "Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose" 131 : 888-893, 1997

8 Nahata MC, "Pharmacokinetics of ibuprofen in febrile children" 40 : 427-428, 1991

9 Onouchi Z, "Overview of pharmacological treatment of Kawasaki disease" 58 : 813-822, 1999

10 Rowley AH, "Oligoclonal IgA response in the vascular wall in acute Kawasaki disease" 166 : 1334-1343, 2001

11 Burns JC, "Kawasaki disease: A brief history" 106 : E27-, 2000

12 Rowley AH, "Kawasaki disease. In : Nelson textbook of pediatrics. 18th ed" WB Saunders Co 1036-1042, 2007

13 Lee JH, "Kawasaki disease with Reye syndrome: report of one case" 33 : 67-71, 1992

14 Rowley AH, "IgA plasma cells in vascular tissue of patients with Kawasaki syndrome" 159 : 5946-5955, 1997

15 Rowley AH, "IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease" 182 : 1183-1191, 2000

16 Mulberg AE, "Identification and treatment of nonsteroidal anti-inflammatory drug-induced gastroduodenal injury in children" 147 : 1280-1281, 1993

17 Dajani AS, "Guidelines for long-term management of patients with Kawasaki disease: Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association" 89 : 916-922, 1994

18 Matsubara T, "Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease" 128 : 701-703, 1996

19 Newburger JW, "Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association" 114 : 1708-1733, 2004

20 Dajani AS, "Diagnosis and therapy of Kawasaki disease in children" 87 : 1776-1780, 1993

21 Catella-Lawson F, "Cylooxygenase inhibitors and the antiplatelet effects of aspirin" 345 : 1809-1817, 2001

22 Yoshikawa J, "Cross-sectional echocardiographic diagnosis of coronary artery aneurysms in patients with the mucocutaneous lymph node syndrome" 59 : 133-139, 1979

23 Kurotobi S, "Coronary diameter in normal infants, children and patients with Kawasaki disease" 44 : 1-4, 2002

24 Ichida F, "Coronary artery involvement in Kawasaki syndrome in Manhattan, New York: risk factors and role of aspirin" 80 : 828-835, 1987

25 de Zorzi A, "Coronary artery dimensions may be misclassified as normal in Kawasaki disease" 133 : 254-258, 1998

26 Crystal MA, "Coronary artery dilation after Kawasaki disease for children within the normal range" 1-6, 2008

27 Food and Drug Administration U.S. Department of Health and Human Services, "Concomitant use of ibuprofen and aspirin" 21 : 73-74, 2007

28 Burns JC, "Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group" 118 : 680-686, 1991

29 Brown TJ, "CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease" 184 : 940-943, 2001

30 Behan MW, "Antiplatelet therapy in cardiovascular disease" 80 : 155-164, 2004

31 Kawasaki T, "Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children" 16 : 178-222, 1967

32 Newburger JW, "A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome" 324 : 1633-1639, 1991

33 Newburger JW, "A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki disease" 324 : 1633-1639, 1991